Does intravitreal injection of bevacizumab have an effect on the blood-aqueus barrier function?
Ziemssen
F
F
Warga
M
M
Neuhann
I M
IM
Leitritz
M
M
Biester
S
S
Grisanti
S
S
Bartz-Schmidt
K U
KU
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000097:blood / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000097:blood / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D018916:Blood-Aqueous Barrier / Q000187:drug effects*; D005260:Female; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy; D008297:Male; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab